# A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.

> **NCT04494984** · PHASE2,PHASE3 · COMPLETED · sponsor: **Inmunova S.A.** · enrollment: 243 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** INM005
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04494984
- **Lead sponsor:** Inmunova S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2020-11-23
- **Final completion:** 2020-12-30
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494984, "A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04494984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*